News

Press Release

June 3, 2021

MEC Announces Submission Of Listing Statement To The CSE In Coordination with Albert Labs RTO

Albert Labs going public soon. JUNE 03 , 2021 - VANCOUVER, BRITISH COLUMBIA, ME Resource Corp…

Albert Labs

Love0

Press Release

May 25, 2021

Adding To Their Expert Team, Albert Labs Announces The Formation And Chairs Of Its Two Advisory Boards.

Professor Jo Neill and Parminder Singh bring psychopharmacology and IP protection & licensing expertise to…

Albert Labs

Love0

Interviews

May 13, 2021

Interviewing Dr Malcolm Barratt-johnson

Interviewing Dr Malcolm Barratt-Johnson Chief Medical Officer. Malcolm shares a deep insight into Albert Labs,…

Albert Labs 0

Love0

Interviews

May 6, 2021

The Psychedelic Therapeutics and Drug Development Conference

In this panel, field expert’s Dr Malcolm Barratt-Johnson and Graeme McFarlane will discuss the work…

Albert Labs 0

Love0

Interviews

April 29, 2021

Clinical Trials & RWE | Microdose Psychedelic Capital: Apr 2021

"Clinical Trials & RWE" Featuring Malcolm Barratt-Johnson, Matthew W. Johnson, PhD, MA, & Andrew Pendrill.…

Albert Labs 0

Love0

News

April 15, 2021

Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs 0

Love0

Press Release

April 14, 2021

Albert Labs Appoints Mackie Research As Lead Agent For Private Placement Of Proceeds Up To $4 Million Pre-RTO

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary…

Albert Labs

Love0

Press Release

March 5, 2021

MEC signs RTO definitive agreement to acquire Albert Labs, a European psychedelic drug researcher & developer

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary…

Albert Labs

Love0

Interviews

January 28, 2021

Introducing Albert Labs | Microdose Psychedelic Capital: Jan 2021

Introducing Albert Labs at Microdose Psychedelic Capital: Jan 2021 Featuring Malcolm Barratt-Johnson, Chand Jagpal &…

Albert Labs 0

Love0

Press Release

January 5, 2021

MEC announces letter of intent to acquire Albert Labs, a European psychedelic drug researcher & developer

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based…

Albert Labs

Love0

MEC Announces Submission Of Listing Statement To The CSE In Coordination with Albert Labs RTO

Adding To Their Expert Team, Albert Labs Announces The Formation And Chairs Of Its Two Advisory Boards.

Interviewing Dr Malcolm Barratt-johnson

The Psychedelic Therapeutics and Drug Development Conference

Clinical Trials & RWE | Microdose Psychedelic Capital: Apr 2021

Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs Appoints Mackie Research As Lead Agent For Private Placement Of Proceeds Up To $4 Million Pre-RTO

MEC signs RTO definitive agreement to acquire Albert Labs, a European psychedelic drug researcher & developer

Introducing Albert Labs | Microdose Psychedelic Capital: Jan 2021

MEC announces letter of intent to acquire Albert Labs, a European psychedelic drug researcher & developer

Innovative mental health medicines for patients with unmet needs.

Navigate

About

Team

Contact

Connect

info@albertlabs.com

Get in touch

About Salient